Skip to content

NANOVIRICIDES, INC.: 10-K filed 2024-09-27

What NANOVIRICIDES, INC. reported in its annual report filed 2024-09-27 (fiscal FY 2024): 38 published measures, 76 facts as tagged in accession 0001410578-24-001650.

This filing

Form
10-K (annual report)
Filed
2024-09-27
Fiscal period
fiscal FY 2024
Accession
0001410578-24-001650 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NANOVIRICIDES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-3012,822,853USD
At 2023-06-3016,899,880USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-301,358,776USD
At 2023-06-302,034,250USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-3011,464,077USD
At 2023-06-3014,865,630USD
At 2022-06-3023,082,025USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-06-304,797,778USD
At 2023-06-308,149,808USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2024-06-30-8,294,146USD366
2022-07-01 to 2023-06-30-8,588,573USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-07-01 to 2024-06-30-6,315,507USD366
2022-07-01 to 2023-06-30-5,670,051USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-07-01 to 2024-06-30156,560USD366
2022-07-01 to 2023-06-30151,712USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-07-01 to 2024-06-303,120,037USD366
2022-07-01 to 2023-06-30-94,788USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-07-01 to 2024-06-30-156,560USD366
2022-07-01 to 2023-06-30-151,712USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-139,374,895USD
At 2023-06-30-131,080,749USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-07-01 to 2024-06-3011,871,054shares366
2022-07-01 to 2023-06-3011,626,220shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-07-01 to 2024-06-3011,871,054shares366
2022-07-01 to 2023-06-3011,626,220shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-07-01 to 2024-06-30-0.7USD/shares366
2022-07-01 to 2023-06-30-0.74USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-07-01 to 2024-06-30-0.7USD/shares366
2022-07-01 to 2023-06-30-0.74USD/shares365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-06-307,512,463USD
At 2023-06-308,106,647USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-07-01 to 2024-06-30-8,516,111USD366
2022-07-01 to 2023-06-30-8,943,468USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-304,970,520USD
At 2023-06-308,445,294USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-301,358,776USD
At 2023-06-30534,250USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-06-30325,308USD
At 2023-06-30333,578USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-07-01 to 2024-06-308,516,111USD366
2022-07-01 to 2023-06-308,943,468USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-07-01 to 2024-06-305,437,297USD366
2022-07-01 to 2023-06-306,392,414USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-3013,144,055shares
At 2023-06-3011,698,497shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-304,797,778USD
At 2023-06-308,149,808USD
At 2022-06-3014,066,359USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-06-30150,838,832USD
At 2023-06-30145,946,257USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-06-3014,966,286USD
At 2023-06-3014,809,726USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-06-307,453,823USD
At 2023-06-306,703,079USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2024-06-30325,308USD
At 2023-06-30333,578USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-06-30262,467USD
At 2023-06-30143,760USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2024-06-300USD
At 2023-06-300USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-07-01 to 2024-06-30-8,294,146USD366
2022-07-01 to 2023-06-30-8,588,573USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2024-06-303,078,814USD366
2022-07-01 to 2023-06-302,551,054USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-07-01 to 2024-06-30750,744USD366
2022-07-01 to 2023-06-30739,259USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2023-07-01 to 2024-06-308,270USD366
2022-07-01 to 2023-06-308,270USD365

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2023-07-01 to 2024-06-3049,808USD366
2022-07-01 to 2023-06-30938USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2023-07-01 to 2024-06-30271,773USD366
2022-07-01 to 2023-06-30355,833USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-07-01 to 2024-06-30221,965USD366
2022-07-01 to 2023-06-30354,895USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2023-07-01 to 2024-06-300USD366

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2022-07-01 to 2023-06-30938USD365

Inspect the source

Entity
NANOVIRICIDES, INC. / CIK 0001379006
Captured
2026-09-20T07:58:03.748Z
SEC response SHA-256
5d15adcbc42d7ac8bfebbf748da8ae31563dd5d02e790dc3e1b9bde076c805d2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001379006.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))